Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow Post author:Sam Post published:November 29, 2017 Post category:BioPharma Sanofi’s setback could open the door for rival drugmaker Takeda. Source: BioSpace You Might Also Like Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now November 28, 2017 Biogen's CSO Quietly Leaves, But Will Still Get R&D Funding From the Biotech Giant May 14, 2017 Valeant Providing Reporters With an Earnings Metric the SEC Ordered it to Stop Using November 9, 2017
Valeant Providing Reporters With an Earnings Metric the SEC Ordered it to Stop Using November 9, 2017
